Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Recruiting NCT05617469

DLCS for Predicting Neoadjuvant Chemotherapy Response

Conditions: Gastric Cancer, CT Images, Deep Learning, Neoadjuvant Chemotherapy, Tumor Regression Grade

Sex: All
Ages: 18 Years – 80 Years
Enrollment: 1100
Sponsor: Zhejiang Cancer Hospital

Location: China

Summary

The early noninvasive screening of patients suitable for neoadjuvant chemotherapy (NCT) is essential for personalized treatment in locally advanced gastric cancer (LAGC). The aim of this study was to develop and visualized a radio-clinical biomarker from pretreatment oversampled CT images to predict the response and prognosis to NCT in LAGC patients.

Eligibility Criteria

Inclusion Criteria:1) patients with GC/EGJC confirmed by pathological examination; 2) patients who underwent D2 lymphadenectomy; 3) patients who received at least two cycles of preoperative chemotherapy; 4) patients with negative resection margins; and 5) patients with complete CT image data and clinical data.Exclusion Criteria:1) patients unable to undergo D2 radical gastrectomy after neoadjuvant therapy; and 2) patients with incomplete CT images and clinical data.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05617469). StuddyBuddy aggregates publicly available trial information.